These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 32686686)

  • 1. Landscape of somatic single nucleotide variants and indels in colorectal cancer and impact on survival.
    Zaidi SH; Harrison TA; Phipps AI; Steinfelder R; Trinh QM; Qu C; Banbury BL; Georgeson P; Grasso CS; Giannakis M; Adams JB; Alwers E; Amitay EL; Barfield RT; Berndt SI; Borozan I; Brenner H; Brezina S; Buchanan DD; Cao Y; Chan AT; Chang-Claude J; Connolly CM; Drew DA; Farris AB; Figueiredo JC; French AJ; Fuchs CS; Garraway LA; Gruber S; Guinter MA; Hamilton SR; Harlid S; Heisler LE; Hidaka A; Hopper JL; Huang WY; Huyghe JR; Jenkins MA; Krzyzanowski PM; Lemire M; Lin Y; Luo X; Mardis ER; McPherson JD; Miller JK; Moreno V; Mu XJ; Nishihara R; Papadopoulos N; Pasternack D; Quist MJ; Rafikova A; Reid EEG; Shinbrot E; Shirts BH; Stein LD; Teney CD; Timms L; Um CY; Van Guelpen B; Van Tassel M; Wang X; Wheeler DA; Yung CK; Hsu L; Ogino S; Gsur A; Newcomb PA; Gallinger S; Hoffmeister M; Campbell PT; Thibodeau SN; Sun W; Hudson TJ; Peters U
    Nat Commun; 2020 Jul; 11(1):3644. PubMed ID: 32686686
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The heterogeneous impact of targeted therapy on the prognosis of stage III/IV colorectal cancer patients with different subtypes of TP53 mutations.
    Chen J; Chang X; Li X; Liu J; Wang N; Wu Y; Zheng L; Nie X
    Cancer Med; 2023 Dec; 12(24):21920-21932. PubMed ID: 38063316
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multiregion ultra-deep sequencing reveals early intermixing and variable levels of intratumoral heterogeneity in colorectal cancer.
    Suzuki Y; Ng SB; Chua C; Leow WQ; Chng J; Liu SY; Ramnarayanan K; Gan A; Ho DL; Ten R; Su Y; Lezhava A; Lai JH; Koh D; Lim KH; Tan P; Rozen SG; Tan IB
    Mol Oncol; 2017 Feb; 11(2):124-139. PubMed ID: 28145097
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    Li AJ; Li HG; Tang EJ; Wu W; Chen Y; Jiang HH; Lin MB; Yin L
    World J Gastroenterol; 2018 Feb; 24(5):631-640. PubMed ID: 29434452
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heterogeneous mutational profile and prognosis conferred by TP53 mutations in appendiceal mucinous neoplasms.
    Zhu X; Salhab M; Tomaszewicz K; Meng X; Mathew C; Bathini V; Switzer B; Walter O; Cosar EF; Wang X; Lambert LA; Hutchinson LM
    Hum Pathol; 2019 Mar; 85():260-269. PubMed ID: 30458197
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multi gene mutation signatures in colorectal cancer patients: predict for the diagnosis, pathological classification, staging and prognosis.
    Zhuang Y; Wang H; Jiang D; Li Y; Feng L; Tian C; Pu M; Wang X; Zhang J; Hu Y; Liu P
    BMC Cancer; 2021 Apr; 21(1):380. PubMed ID: 33836681
    [TBL] [Abstract][Full Text] [Related]  

  • 7. p53 expression status is associated with cancer-specific survival in stage III and high-risk stage II colorectal cancer patients treated with oxaliplatin-based adjuvant chemotherapy.
    Oh HJ; Bae JM; Wen X; Jung S; Kim Y; Kim KJ; Cho NY; Kim JH; Han SW; Kim TY; Kang GH
    Br J Cancer; 2019 Apr; 120(8):797-805. PubMed ID: 30894685
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Performance validation of an amplicon-based targeted next-generation sequencing assay and mutation profiling of 648 Chinese colorectal cancer patients.
    Wang Y; Liu H; Hou Y; Zhou X; Liang L; Zhang Z; Shi H; Xu S; Hu P; Zheng Z; Liu R; Tang T; Ye F; Liang Z; Bu H
    Virchows Arch; 2018 Jun; 472(6):959-968. PubMed ID: 29705968
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel DNA variants and mutation frequencies of hMLH1 and hMSH2 genes in colorectal cancer in the Northeast China population.
    Hu F; Li D; Wang Y; Yao X; Zhang W; Liang J; Lin C; Ren J; Zhu L; Wu Z; Li S; Li Y; Zhao X; Cui B; Dong X; Tian S; Zhao Y
    PLoS One; 2013; 8(4):e60233. PubMed ID: 23573243
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mucinous adenocarcinoma of the colon and rectum: A genomic analysis.
    Reynolds IS; O'Connell E; Fichtner M; McNamara DA; Kay EW; Prehn JHM; Furney SJ; Burke JP
    J Surg Oncol; 2019 Dec; 120(8):1427-1435. PubMed ID: 31729037
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutations and polymorphisms in TP53 gene--an overview on the role in colorectal cancer.
    Naccarati A; Polakova V; Pardini B; Vodickova L; Hemminki K; Kumar R; Vodicka P
    Mutagenesis; 2012 Mar; 27(2):211-8. PubMed ID: 22294769
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of colorectal cancer patients with tumors carrying the TP53 mutation on the codon 72 proline allele that benefited most from 5-fluorouracil (5-FU) based postoperative chemotherapy.
    Godai TI; Suda T; Sugano N; Tsuchida K; Shiozawa M; Sekiguchi H; Sekiyama A; Yoshihara M; Matsukuma S; Sakuma Y; Tsuchiya E; Kameda Y; Akaike M; Miyagi Y
    BMC Cancer; 2009 Dec; 9():420. PubMed ID: 19954513
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic and predictive factors in colorectal cancer: Kirsten Ras in CRC (RASCAL) and TP53CRC collaborative studies.
    Russo A; Bazan V; Agnese V; Rodolico V; Gebbia N
    Ann Oncol; 2005 May; 16 Suppl 4():iv44-49. PubMed ID: 15923428
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TP53 somatic mutations are associated with somatic mitogenome substitutions but not indels in colorectal cancer cells.
    Skonieczna K; Jawień A; Marszałek A; Grzybowski T
    J Gene Med; 2019 Jan; 21(1):e3063. PubMed ID: 30548163
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High prevalence of TP53 loss and whole-genome doubling in early-onset colorectal cancer.
    Kim JE; Choi J; Sung CO; Hong YS; Kim SY; Lee H; Kim TW; Kim JI
    Exp Mol Med; 2021 Mar; 53(3):446-456. PubMed ID: 33753878
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The TP53 colorectal cancer international collaborative study on the prognostic and predictive significance of p53 mutation: influence of tumor site, type of mutation, and adjuvant treatment.
    Russo A; Bazan V; Iacopetta B; Kerr D; Soussi T; Gebbia N;
    J Clin Oncol; 2005 Oct; 23(30):7518-28. PubMed ID: 16172461
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical significance of frequent somatic mutations detected by high-throughput targeted sequencing in archived colorectal cancer samples.
    Dallol A; Buhmeida A; Al-Ahwal MS; Al-Maghrabi J; Bajouh O; Al-Khayyat S; Alam R; Abusanad A; Turki R; Elaimi A; Alhadrami HA; Abuzenadah M; Banni H; Al-Qahtani MH; Abuzenadah AM
    J Transl Med; 2016 May; 14(1):118. PubMed ID: 27146902
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of neuroendocrine differentiation and KRAS/NRAS/BRAF/PIK3CA/TP53 mutation status in primary and metastatic colorectal cancer.
    Kleist B; Kempa M; Novy M; Oberkanins C; Xu L; Li G; Loland C; Poetsch M
    Int J Clin Exp Pathol; 2014; 7(9):5927-39. PubMed ID: 25337237
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Different hotspot p53 mutants exert distinct phenotypes and predict outcome of colorectal cancer patients.
    Hassin O; Nataraj NB; Shreberk-Shaked M; Aylon Y; Yaeger R; Fontemaggi G; Mukherjee S; Maddalena M; Avioz A; Iancu O; Mallel G; Gershoni A; Grosheva I; Feldmesser E; Ben-Dor S; Golani O; Hendel A; Blandino G; Kelsen D; Yarden Y; Oren M
    Nat Commun; 2022 May; 13(1):2800. PubMed ID: 35589715
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TP53 mutation at early stage of colorectal cancer progression from two types of laterally spreading tumors.
    Sakai E; Fukuyo M; Matsusaka K; Ohata K; Doi N; Takane K; Matsuhashi N; Fukushima J; Nakajima A; Kaneda A
    Cancer Sci; 2016 Jun; 107(6):820-7. PubMed ID: 26991699
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.